In February 2013, Rosetta Capital completed a secondary transaction to acquire a portfolio of thirteen life sciences assets from Karolinska Development, the investment arm of Karolinska Institutet, a leading university in Sweden.
The sale portfolio consists of holdings in Akinion Pharmaceuticals, Aprea Therapeutics, Axelar, Biosergen, Clanotech, Dilafor, Inhalation Sciences, NeoDynamics, NovaSAID, Pergamum, Promimic, and Umecrine Mood.
Rosetta has worked closely with a number of Karolinska portfolio companies including Aprea Therapeutics which had a successful IPO on NASDAQ US in 2019; and Biosergen and Modus Therapeutics which listed on NASDAQ First North in 2021.
Supporting portfolio companies for the next growth phase
Rosetta Capital is committed to supporting the portfolio companies acquired in the transaction through the growth phase and has made several follow-on investments.
Rosetta partners Jonathan Hepple and Ken MacLeod have joined the boards of acquired portfolio companies and are actively involved in strategic decision making.
The basket transaction being announced today is a further important milestone for the Company and delivers against that communicated goal. We are delighted to welcome Rosetta Capital as co-shareholders in ReNeuron, Immunocore and Inivata and we welcome their expertise and experience. We are looking forward to continuing to work with the management teams of the Company’s holdings in delivering sustainable value and positive long-term shareholder returns.”
Tim Creed and Ben Wicks
Portfolio Managers at Schroder UK Public Private Trust plc